To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

Eur J Cancer. 2006 Oct;42(15):2472-9. doi: 10.1016/j.ejca.2006.04.023. Epub 2006 Sep 11.


Introduction: The objective of this study was to evaluate dynamic contrast-enhanced Doppler ultrasound (DCE-US) with perfusion software (Vascular Recognition Imaging) and contrast agent injection as a predictor of tumour response, progression-free survival (PFS) and overall survival (OS).

Patients and methods: Thirty patients with a metastatic renal cell carcinoma (RCC) already enrolled in a double-blind randomised study were evaluated. Examinations were performed at baseline, and after 3 and 6 weeks on sorafenib or a placebo in patients with tumour targets that were accessible to DCE-US.

Results: A total of 85 examinations were performed, 30 at baseline, 28 at 3 weeks and 27 at 6 weeks. The combination of a decrease in contrast uptake exceeding 10% and stability or a decrease in tumour volume allowed us to discriminate seven good responders and 20 poor responders at 3 weeks. There was a statistically significant difference in PFS (p=10(-4)) and OS (p=10(-4)) between good and poor responders.

Conclusion: DCE-US is a new noninvasive imaging technique which might be an effective tool for evaluating antiangiogenic drugs in renal cancer.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / drug therapy
  • Contrast Media
  • Disease Progression
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Phospholipids
  • Pilot Projects
  • Pyridines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sorafenib
  • Sulfur Hexafluoride
  • Survival Analysis
  • Treatment Outcome
  • Ultrasonography, Doppler / methods*


  • Antineoplastic Agents
  • Benzenesulfonates
  • Contrast Media
  • Phenylurea Compounds
  • Phospholipids
  • Pyridines
  • contrast agent BR1
  • Niacinamide
  • Sorafenib
  • Sulfur Hexafluoride